You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ER-Positive Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Triple Negative Breast Cancer Trial in Gothenburg (Imatinib 400 MG Oral Tablet)

Not yet recruiting
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Imatinib 400 MG Oral Tablet
  • Gothenburg, Sweden
    Barbro Linderholm
Feb 1, 2023

HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving

Completed
  • Breast Neoplasms
  • NET or NCT
  • Haidian, Beijing, China
    Peking University Cancer Hospital
Dec 30, 2022

Breast Cancer Trial in Boston, Danvers (Ribociclib, Endocrine therapy)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Estrogen Receptor Positive Breast Cancer Trial in Edmonton (Estradiol)

Active, not recruiting
  • Estrogen Receptor Positive Breast Cancer
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Feb 1, 2023

Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (OP-1250, Fulvestrant, Anastrozole)

Not yet recruiting
  • Breast Cancer
  • +4 more
  • (no location specified)
Aug 31, 2023

Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,

Recruiting
  • Premenopausal Breast Cancer
  • +2 more
  • Taipei City, Taiwan
    Department of Oncology, National Taiwan University Hospital
Feb 7, 2023

Breast Cancer, ER Positive Breast Cancer Trial in Lebanon (Letrozole 2.5mg)

Recruiting
  • Breast Cancer
  • ER Positive Breast Cancer
  • Letrozole 2.5mg
  • Lebanon, New Hampshire
  • +1 more
Dec 19, 2022

Breast Cancer Trial in Beijing (18F-FES PET/CT scan)

Recruiting
  • Breast Cancer
  • 18F-FES PET/CT scan
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 4, 2022

ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer Trial (Elacestrant, Tamoxifen, Letrozole 2.5mg)

Not yet recruiting
  • ER-positive Breast Cancer
  • +3 more
  • (no location specified)
Aug 22, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8 Trial in San Francisco (Pembrolizumab,

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Prognostic Stage IV Breast Cancer AJCC v8
  • Pembrolizumab
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 5, 2023

ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer Trial in Madison, Milwaukee (Onapristone, Fulvestrant)

Recruiting
  • ER-positive Breast Cancer
  • +2 more
  • Madison, Wisconsin
  • +1 more
Jul 7, 2022

Breast Cancer Trial (Letrozole, Atezolizumab)

Withdrawn
  • Breast Cancer
  • (no location specified)
Jun 10, 2022

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Alpelisib, Tamoxifen, Infigratinib)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Stanford, California
    Stanford University
Nov 16, 2022

Immune Environment in Response to Therapy in Breast Cancer

Recruiting
  • Breast Cancer
  • +3 more
  • Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
  • Philadelphia, Pennsylvania
    Abramson Cancer Center
Sep 15, 2022

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (Palbociclib, trastuzumab, pyrotinib)

Recruiting
  • Estrogen Receptor-positive Breast Cancer
  • HER2-positive Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Hospital
Sep 29, 2021

Assessed by 18F-FES PET/CT in MBC With ER-positive Primary Tumor

Recruiting
  • Breast Cancer
    • Shanghai, Shanghai, China
      Biyun Wang, MD
    Apr 5, 2023

    ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer Trial in Luoyang, Shanghai (TFX06 tablet)

    Recruiting
    • ER+, HER2- Advanced Breast Cancer
    • Metastatic Breast Cancer
    • TFX06 tablet
    • Luoyang, Henan, China
    • +1 more
    Jun 25, 2023

    ER-Positive Breast Cancer, HER2-negative Breast Cancer Trial in Houston (Fulvestrant Run-In, No Fulvestrant Run-In)

    Recruiting
    • ER-Positive Breast Cancer
    • HER2-negative Breast Cancer
    • Fulvestrant Run-In
    • No Fulvestrant Run-In
    • Houston, Texas
      Houston Methodist Cancer Center
    Mar 23, 2022

    Gut and Tumor Microbiome in Advanced ER-positive and

    Not yet recruiting
    • Breast Cancer
    • Melanoma
    • Observation
    • (no location specified)
    Nov 6, 2023

    ER+ HER2- Advanced Breast Cancer Trial in Chuo-ku, Kashiwa, Koto-ku (AZD9833)

    Active, not recruiting
    • ER+ HER2- Advanced Breast Cancer
    • Chuo-ku, Japan
    • +2 more
    Jan 24, 2023

    Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based

    Not yet recruiting
    • Breast Cancer
    • Cancer of the Breast
    • VENTANA MIB-1 Ki67 assay
    • +4 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Apr 18, 2023

    Breast Cancer Trial (Giredestrant, Giredestrant plus triptorelin, Anastrozole plus triptorelin)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jun 13, 2023

    Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)

    Not yet recruiting
    • Breast Cancer
    • Ovarian Function Suppression + Aromatase Inhibitor
    • Adjuvant Chemotherapy + Ovarian Function Suppression
    • (no location specified)
    May 19, 2023

    Breast Cancer Stage IV Trial in Irvine (Gallium-68)

    Recruiting
    • Breast Cancer Stage IV
    • Irvine, California
      Hoag Memorial Hospital Presbyterian
    May 26, 2023